Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
| ▸ | ASPH | Q12797 | 1/20 | 0.40 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10324220 | 0.92 | KEAP1 (0.46) | KEAP1CYP3A4SLC9A1NFE2L2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10322678 | 0.90 | KEAP1 (0.44) | KEAP1CYP3A4SLC9A1NFE2L2ALDH1A1 | |
| SCHEMBL23948545 | 0.84 | SLC9A1 (0.49) | SLC9A1ALDH1A1GAAKMT2ACASP1 | |
| SCHEMBL406782 | 0.84 | KEAP1 (0.50) | KEAP1CYP3A4SLC9A1NFE2L2ALDH1A1 | |
| SCHEMBL14331830 | 0.83 | KEAP1 (0.50) | KEAP1NFE2L2ALDH1A1POLBKDM4E | |
| SCHEMBL24338031 | 0.83 | KEAP1 (0.52) | KEAP1CYP3A4NFE2L2ALDH1A1POLB | |
| SCHEMBL9821003 | 0.82 | GAA (0.45) | CYP3A4SLC9A1ALDH1A1POLBGAA | |
| Ammonia Solution, Strong SCHEMBL15377820 | 0.81 | KEAP1 (0.50) | KEAP1CYP3A4NFE2L2ALDH1A1POLB | |
| SCHEMBL16539867 | 0.81 | GAA (0.55) | KEAP1CYP3A4SLC9A1ALDH1A1POLB | |
| SCHEMBL29488312 | 0.81 | KEAP1 (0.48) | KEAP1NFE2L2ALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018138050-A1 | CONDENSED BICYCLIC HETEROCYCLENE DERIVATIVES AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-02 | — | — | WO | disclosed |
| WO-2018138050-A1 | CONDENSED BICYCLIC HETEROCYCLENE DERIVATIVES AS PEST CONTROL AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-02 | — | — | WO | disclosed |
| EP-2785699-B1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | GENENTECH INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | disclosed |
| EP-2785699-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| US-8809331-B2 | Aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130157999-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013079494-A1 | 2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| CN-101511836-A | Fused pyrimido compounds | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| EP-2046793-A2 | FUSED PYRIMIDO COMPOUNDS | AstraZeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040951-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008003958-A2 | FUSED PYRIMIDO COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | KEAP1 611/4885CYP3A4 71/4885SLC9A1 3178/4885 |
| US-20130157999-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, P2RX6 | KEAP1 572/4885CYP3A4 3703/4885SLC9A1 2334/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | KEAP1 1178/4885CYP3A4 3846/4885SLC9A1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.